Lifitegrast
Pronunciation
(lif i TEG rast)
Index Terms
- Lifitegrast Sodium
Dosage Forms
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Ophthalmic:
Xiidra: 5% (5 ea)
Brand Names: U.S.
- Xiidra
Pharmacologic Category
- Lymphocyte Function-Associated Antigen 1 (LFA-1) Antagonist
Pharmacology
Lifitegrast binds to the integrin lymphocyte function-associated antigen-1 (LFA-1) and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1).
Use: Labeled Indications
Dry eye disease: Treatment of the signs and symptoms of dry eye disease (DED).
Contraindications
Hypersensitivity to lifitegrast or any component of the formulation.
Dosing: Adult
Dry eye disease: Ophthalmic: Instill 1 drop into each eye every 12 hours.
Dosing: Geriatric
Refer to adult dosing.
Dosing: Renal Impairment
There are no dosage adjustments provided in the manufacturer’s labeling.
Dosing: Hepatic Impairment
There are no dosage adjustments provided in the manufacturer’s labeling.
Administration
For topical ophthalmic use only. Remove contact lenses prior to administration and wait 15 minutes before reinserting. Do not touch the eye or surrounding area or any surface with the dropper tip to avoid contamination; discard single use container and unused solution after administration.
Storage
Store at 20°C to 25°C (68°F to 77°F). Store single-use containers in the original foil pouch.
Drug Interactions
There are no known significant interactions.
Adverse Reactions
5% to 25%:
Gastrointestinal: Dysgeusia
Local: Application site irritation
Ophthalmic: Decreased visual acuity
1% to 5%:
Central nervous system: Headache
Ophthalmic: Blurred vision, conjunctival hyperemia, eye discharge, eye discomfort, eye irritation, eye pruritus, increased lacrimation
Respiratory: Sinusitis
Warnings/Precautions
Special Populations:
• Contact lens wearers: Remove contact lens prior to administration and wait 15 minutes before reinserting.
Pregnancy Considerations
Adverse events were observed in some animal reproduction studies following intravenous administration. Systemic exposure following ophthalmic administration is low. In general, if ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctual occlusion to decrease potential exposure to the fetus (Samples 1988)
Patient Education
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience eye irritation, change in taste, or blurred vision (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
